Research News

In a major scientific breakthrough, researchers from McMaster University, Cleveland Clinic, and the Case Comprehensive Cancer Center have uncovered how a protein commonly linked to Alzheimer’s disease also plays a critical role in the spread of lung cancer to the brain. The discovery could pave the way for repurposing existing Alzheimer’s drugs to halt or slow brain metastases in cancer patients.

Researchers at the University of Illinois Urbana-Champaign have developed an innovative magnetic resonance imaging (MRI) method capable of noninvasively mapping metabolic activity in the brain, offering new insights into neurological diseases.

Pfizer unveiled very encouraging topline results from its Phase 3 BASIS clinical trial (NCT03938792). The study examined once‑weekly, under‑skin injections of HYMPAVZI (marstacimab) in adolescents and adults (12 years+) living with hemophilia A or B complicated by inhibitors an antibody that can neutralize traditional factor replacement therapy.

In a landmark study published recently in Chinese Neurosurgical Journal, Chinese researchers have identified the protein FAM111B as a crucial molecular accelerator in glioma, the most common and deadly form of primary brain cancer in adults.

Researchers at the University of Texas at Arlington (UTA) have identified a novel molecular mechanism by which chronic inflammation impairs cholesterol metabolism, potentially paving the way for new therapeutic strategies targeting inflammatory diseases and cardiovascular disorders.

Biological therapies have significantly improved the quality of life for many individuals suffering from severe asthma. However, new research from Karolinska Institutet in Sweden reveals that some inflammatory immune cells may persist in the bloodstream even after treatment, raising questions about the long-term effectiveness of these drugs.

A recent study by researchers at the Technical University of Munich (TUM) has uncovered a molecular mechanism that may explain how inflammation leads to neurodegeneration in patients with multiple sclerosis

A pioneering gene therapy engineered by researchers at the University of California San Diego (UCSD) School of Medicine demonstrates remarkable promise in halting, and potentially reversing, cognitive decline in preclinical Alzheimer’s models.

Eli Lilly and Company announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes